key: cord-0300502-zu2wpd26 authors: Barak Mizrahi, Maytal Bivas-Benita; Nir Kalkstein, Pinchas Akiva; Chen Yanover, Yoav Yehezkelli; Yoav Kessler, Sharon Hermoni Alon; Eitan Rubin, Gabriel Chodick title: Results of an early second PCR test performed on SARS-CoV-2 positive patients may indicate risk for severe COVID-19 date: 2021-02-12 journal: nan DOI: 10.1101/2021.02.09.21251371 sha: 6fb2332b97c083130b4aa8977b927f8fde83c672 doc_id: 300502 cord_uid: zu2wpd26 nan The COVID-19 pandemic is continuing to spread, surpassing 92M confirmed cases and 2M deaths globally as of January 2021 1 . Although survival rates have gradually improved by the development of successful treatment protocols for moderate and severe patients, the disease continues to claim lives and containment is proven difficult [2] [3] [4] [5] [6] . Widespread severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) testing is regarded as best practice for detection of infection and epidemiological surveillance. Strategies for detection and containment of COVID-19 have evolved and now that testing has become more available it is performed both in community-based sites and in hospitals. Multiple testing following exposure and diagnosis of COVID -19 patients has been used to evaluate infectiousness and assure resolution of infection, especially considering the known silent spread by infected individuals that are asymptomatic [7] [8] [9] [10] [11] . Current SARS-CoV-2 infection is mostly tested using reverse transcription quantitative polymerase chain reaction of viral genes (RT-qPCR)-based assays, determining presence of viral genetic signatures 12 . This test is highly specific, resulting in minimal false-positive rates and is considered the most accurate COVID-19 diagnosis method 13, 14 . However, a positive PCR test is unable to report the exact disease timeline of the patients, detect whether they are still infectious or determine what will be the severity of their disease. It was therefore suggested that frequent testing serve as a surveillance testing regimen to enable better detection of the infectious window and disease course 15 . tests) could be SARS-CoV-2 positive again during their isolation period. This highlighted that negative test results can appear during the disease timeline but not necessarily determine infection resolution 18 . While multiple testing may unfold the disease timeline, it is unclear whether it could indicate disease severity following COVID-19 diagnosis. To evaluate whether additional testing following diagnosis could indicate severe illness, we analyzed electronic health records (EHR) from Maccabi Healthcare Services (MHS), the second largest Health Maintenance Organization (HMO) in Israel, which included longitudinal results of SARS-CoV-2 testing during the COVID-19 outbreak. Our study investigated the association between PCR results of a second test performed 2-7 days after a positive COVID-19 diagnosis and deterioration to severe disease. We analyzed different age groups, different clinical settings and patients at different stages in their disease timeline with the aim of supporting physicians' risk assessment early for providing appropriate care to those at risk. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 12, 2021. ; https://doi.org/10.1101/2021.02.09.21251371 doi: medRxiv preprint Data from March 1, 2020 to August 9, 2020 included 239,048 adults with records of a SARS-CoV-2 PCR test, among them 15,822 (6.6%) tested positive for the virus (Table 1) . Tested individuals had an average age of 44.1 years and males were 52% of those tested positive. Among those tested positive, we identified 1,683 individuals who also had a second PCR test performed 2-7 days following diagnosis and their disease outcomes were analyzed throughout our study. Another subpopulation we explored was of 3,135 adults who had additional multiple PCR tests between their first and last documented positive SARS-CoV-2 test (defined as a SARS-CoV-2 positive window; see in "Methods" section). The probability to develop a severe disease was evaluated in the study's population stratified to three age groups: 18-59, 60-79 and >80 ( Table 2 ). The overall probability to develop severe COVID-19 was 2.63% in the adult population. The probability of the 18-59 years old age group to deteriorate to severe condition was 0.99% (95% confidence interval (CI) = 0.83-1.16%). The high-risk population of adults older than 60 years showed increased probability to develop severe COVID-19 with a substantial difference between the age groups 60-79 and >80 years old (Probability=8.15% (6.98-9.32%) and 30.62% (26.69-34.54%), respectively). 25 .81%) and 3.53% (2.08-4.97%), respectively). We also measured the probabilities for severe illness among individuals who were not tested a second time to assess if a bias towards a more severe outcome existed in those who tested. The probabilities for severe illness in patients not-tested a second time followed the same trend as those who tested (29.45% (24.07-34.84%) in the >80 years age group; 7.23% (5.99-8.47%) in the 60-79 years and 0.87% (0.70-1.03%) in the 18-59 years). Despite the differences in the probability rates for deterioration in each age group, a positive test was highly associated with deterioration to severe COVID-19 compared to negative test across all ages ( Fig. 1b (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. a. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 12, 2021. ; https://doi.org/10.1101/2021.02.09.21251371 doi: medRxiv preprint b. Blue circles represent individuals who tested negative, orange circles represent individuals who tested positive and green circles represent individuals who were not tested in the week following diagnosis. Grey lines indicate 95% confidence intervals. (b): Log odds ratio (OR) for severe COVID-19 was calculated by the result of a second PCR test taken a week following diagnosis in a defined age group (18-59 years, n=1287; 60-79 years, n=266; >=80 years, n=130). OR>0 indicated larger risk in the population that tested positive compared to the population tested negative. Calculated log odds ratios are presented along with gray lines indicating 95% confidence intervals. Next, we investigated whether the association of the second test result with disease deterioration was dependent on the testing settings. We therefore sub grouped the SARS-CoV-2-positive patients to those tested the second time while admitted to the All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 12, 2021. ; https://doi.org/10.1101/2021.02.09.21251371 doi: medRxiv preprint hospital vs those tested in the community and measured their outcomes. Furthermore, following the previous observations that the population > 60 years is at an increased risk for severe disease and a second PCR test could differentiate between those who will deteriorate, additional analysis on this age subgroup was included (combining the data of both 60-79 and > 80 years old populations). Results showed that 24.8% of adults > 18 and 48.5% of > 60 years old tested a second time within a week following diagnosis while they were admitted to the hospital (Supplementary Table 3 ). The risk for deterioration to severe illness in hospitalized patients was higher than in patients tested in the community and the older population was at increased risk in both settings (For all adults > 18 years: Probability in the hospital = 22.3% (18.31%-26.30%) vs Probability in the community = 1.18% (0.59%-1.78%); For > 60 years: Probability in the hospital = 34.9% (29.09%-40.70%) vs Probability in the community = 6.37% (3.12%-9.62%)). However, the result of the second SARS-CoV-2 PCR test was indicative for severe disease outcome in both settings with higher odds ratio in the community (OR=17.56 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 12, 2021. ; https://doi.org/10.1101/2021.02.09.21251371 doi: medRxiv preprint a. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 12, 2021. c. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Following confirmation of infection by a positive PCR test result, a "positive window" was detected in some patients, which is defined as the period between their first and their last positive test (from diagnosis date to the last positive test). In some patients additional PCR tests were performed within a "positive window" and when the results were negative they were mostly regarded as "false-negative" as they did not indicate disease resolution. To evaluate whether negative test results were still associated with better clinical outcomes, despite knowing viral RNA is still present, we analyzed data of adult patients with a "positive window" that included additional tests in it. A total of 5,823 tests from 3,094 patients with a positive window of up to 3 weeks following diagnosis was followed, of those, 1,799 (30%) were negative ( Fig. 3 ; Supplementary Table 5) . Higher negative test rates were observed the farther they were taken from the date of diagnosis, starting with 4.3% (0.6%-7.9%) on the first day from diagnosis and reaching 42.0% (35.0%-48.9%) by day 21. This increase in negative rate is seen despite being in a positive window and is affected by the time from diagnosis. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Line represents the negative tests rate from day 1 to day 21 following a positive COVID-19 diagnosis. Each time point is calculated by taking a 3 days window (±1 days from day measured) except in the first day which was taken as is. Shaded area represents 95% binomial proportion confidence intervals. Negative COVID-19 test results within a "positive window" are considered insignificant as they do not reflect recovery from COVID-19. To evaluate whether an early second test was indicative of disease severity even in patients which we retrospectively knew had additional SARS-CoV-2-positive test, we analyzed 687 patients with a "positive window" and a second early PCR test ( Fig. 4 ; Supplementary Table 6 ). We analyzed all patients who tested positive and divided them to those with a "positive window" and those without for comparison. Data showed that an early second negative test result in patients with a "positive window" was associated with decreased All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 12, 2021. ; https://doi.org/10.1101/2021.02.09.21251371 doi: medRxiv preprint probability for severe illness compared to a positive test result (>18 years (Fig. 4a ): 3.2% (1.2-6.3%) vs 10.5% (8.0-13.0%); > 60 years (Fig. 4c ): 8.3% (0-19.4%) vs 26.6% (19.7-33.5%)). The association of a second negative test with decreased probability for severe illness was also seen in patients without the "positive window". In the adults >18 years age group, the risk for disease deterioration in the individuals without an early second test was quite similar to that of those who tested negative, while in the > 60 years age group it was slightly higher as it includes those who will become severe but have not tested a second time. An early second SARS-CoV-2 PCR test result was indicative of severe disease outcome in patients with a "positive window" and in patients without it in both age groups, presenting similar OR values ( Fig. 4b and 4d ; Supplementary Table 7 ). These results show that a second negative test in SARS-CoV-2 positive individuals is indicative for decreased probability of disease deterioration whether the patient is in a "positive window" or not. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. c. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Our results suggest that a second SARS-CoV-2 test performed in the week following diagnosis could serve as a tool to identify COVID-19 patients at higher risk of developing a severe condition. In order to estimate the best timing to perform the second PCR test, we analyzed test results performed on all adults >18 years old every day of the first week and their ability to significantly distinguish between those at a higher risk for severe outcomes (Fig. 5) . Data showed that from day 2, and throughout the first week following the first SARS-CoV-2 positive test result, a negative PCR test result was significantly associated with a lower probability for severe disease outcome compared to a positive test result (p<0.05; Supplementary Table 8 ). All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Focusing on the population that had a second test within a week of a positive SARS-CoV-2 result enabled us to look whether testing within a short time interval from diagnosis could give indication to future clinical outcomes and assist physicians in disease management of their patients. As time from exposure to symptom onset is 4-5 days and in symptomatic patients disease worsens within 5-10 days from symptom onset 19,20 , we focused on additional testing within the first week of diagnosis. This is before patients' clinical course becomes clear and those without severe symptoms are sent home for quarantine, away from medical observation. In agreement with current knowledge regarding risk factors for severe outcomes [21] [22] [23] , our data showed that the probability of deteriorating to severe COVID-19 was age-dependent and was most substantial in adults older than 60 years. While adults under 60 years presented 0.99% probability of deterioration, adults aged 60-79 years and >=80 years presented much All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. second PCR test by physicians in both settings, but also the significant value such a test can offer in the community settings to support a more informed clinical decisionmaking. Previous reports have shown that viral dynamics in patients with mild and severe disease differed and that patients with severe illness had higher viral loads and longer virus shedding period compared to mild cases 24, 25 . This analysis may explain our observations as they report peak viral loads in the second week from disease onset in mild cases while the severe cases show continuous high viral loads at the third and fourth week following disease onset. It has therefore been suggested that detection and quantification of viral RNA levels could aid risk-stratification of hospitalized patients 26 . Other efforts are continuously directed towards building tools for predicting disease deterioration of hospitalized patients using lungs CT, biomarkers, blood tests values, respiratory values and vital signs 27-29 . Currently, none of these approaches are All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 12, 2021. results as they reach levels lower than the tests' detection limit 17, [30] [31] [32] [33] [34] . This study shows All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Second PCR testing was able to distinguish between those at higher risk and those at lower risk of deterioration in most days during the first week following the first positive SARS-CoV-2 PCR test. The differences in risk for COVID-19 deterioration were first seen at day two following the positive test and continued through day seven. This Our study has several strengths. First, this unique dataset with longitudinal multiple testing following a positive SARS-CoV-2 test result was available as a result of how COVID-19 response in Israel shaped. At the beginning of the pandemic, Israeli citizens could request a COVID-19 test through multiple channels: the national corona focal point, their general practitioner, directly from their HMO or while visiting the ER in the hospitals. As these systems were not synchronized, individuals were able to get tested several times in short intervals close to the date of diagnosis until concrete national guidelines demanded a reference by the physician for COVID-19 test. Additionally, until mid-July 2020, a SARS-CoV-2 positive individual needed 2 consecutive negative tests in order to end isolation, which added data and the ability to detect a "positive window" of individuals with COVID-19. Second, we used HMO data All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 12, 2021. ; https://doi.org/10.1101/2021.02.09.21251371 doi: medRxiv preprint containing all the patients diagnosed with COVID-19 and analyzed results of all tests that were done both in the hospitals and in the community. This makes this study and its conclusions relevant for the general population and valid in the different settings where COVID-19 patients are cared for. Validating the analysis in the different subgroups and observing repeatedly that a second PCR test is indicative of the probability for severe outcomes increased the confidence in these findings. Our study also has several limitations. First, we were unable to determine what was the reason for the multiple PCR tests performed by the individuals. The additional tests were not done by all SARS-CoV-2 positive patients documented in Maccabi Health Services. Within the week following a positive test we had results of a second PCR test for 10% of the patients 18-59 years old, 14% for ages 60-79 and 32% for patients older than 80. To control for a potential bias, we also analyzed all the patients who tested positive and did not have an early second PCR test. Their risk for severe condition was in the range of those who tested positive/negative the second time within a week from diagnosis. Second, the guidelines for COVID-19 testing in Israel had changed several times during the study period and the inconsistent reasons and frequency for SARS-CoV-2 PCR testing may affect our results. In conclusion, this study explored a new application for multiple SARS CoV-2 PCR testing. While current multiple testing approaches aim to detect COVID-19 early, prevent transmission, contain it and reduce morbidity and mortality, we suggest that additional PCR testing is used in the clinic as an early, wide-spread complementary tool for risk assessment and subsequent appropriate disease management. This could direct appropriate resources and guide clinical testing and isolation of patients at risk. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 12, 2021. cohort included patients whose disease status deteriorated to severe, admitted to the intensive care unit or died as updated by hospital staff. Initially, the definition varied slightly between hospitals but was commonly dictated by the severity of symptoms in the lower respiratory tract, respiratory distress, pneumonia, use of artificial respiration, shock and system failure. SARS-CoV-2-positive patients that were not reported with a severe disease status, including asymptomatic, mild patients or with unknown status, constitute the cohort of infected COVID-19 patients that did not deteriorate to severe condition. We analyzed data of individuals from MHS, who had at least one PCR test for SARS-CoV-2 between March 1, 2020 and August 9, 2020. 239,048 individuals tested for SARS-CoV-2. Overall, 375,558 PCR tests for SARS-CoV-2 were performed during this time period. Patients with COVID-19 infection were identified as those having at least All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 12, 2021. This population was evaluated for its association with COVID-19 severity. Patients with at least two positive SARS-CoV-2 PCR tests and at least one additional test between them were defined as patients with a COVID-19 "positive window". We identified 3,135 adults with a "positive window" and used this subpopulation to analyze whether an early second negative PCR test could be associated with the patients' disease severity, even when they still during an active infection period. Data of COVID-19 patients from the hospitals included hospitalization date, disease severity indication including ICU admission and death. Out of the 15,822 infected patients, 416 (2.63%) had severe outcomes during this study period. We used hospitalization data to define the patients' outcomes and to determine whether the PCR test was performed during hospitalization or in the community. For analyzing the association between the SARS-CoV-2 PCR result of the second test taken after diagnosis and severe outcomes, we included the first PCR test result from days 2-7 following diagnosis date (which was determined by the first positive SARS-CoV-2 PCR test). The risk for severe outcome was calculated for sub-groups divided by the occurrence and result of the additional test (positive test, negative test and not tested). In addition, we calculated the odds ratio for severe outcomes for positive and negative PCR test results in the different ages groups. This analysis was performed for several age All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. We further analyzed the connection between the additional test and whether the test was performed during hospitalization or in the community, for that we used the date the patient entered the hospital and the date of the additional test. Next we analyzed negative tests within a positive window which was defined for patients with at least 2 positive tests, the window range was from the first positive test to the last positive test, we analyzed the results of the tests in this window with relation to the distance in days from the start of the window. For each day we calculate the fraction of negative tests. To find the relevant days that show significant difference in predicting deterioration to severe outcome we run the analysis for each day taking the test if it was the first one during one week from the first positive test. We used chi square test to compute p-value. The study protocol was approved by Maccabi Health Services' institutional review board (0024-20-MHS). Informed consent was waived by the IRB, as all identifying details of the participants were removed before the computational analysis. The data that support the findings of this study originate from Maccabi Health Services. Restrictions apply to the availability of these data and they are therefore not publicly available. Due to restrictions, these data can be accessed only by request to the authors and/or Maccabi Health Services. Analysis code is available at git though it is tailored to the data and the fields of the Maccabi Health Services database. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 12, 2021. ; https://doi.org/10.1101/2021.02.09.21251371 doi: medRxiv preprint WHO Coronavirus Disease (COVID-19) Dashboard Repurposed Antiviral Drugs for Covid-19 -Interim WHO Solidarity Trial Results Remdesivir for the Treatment of Covid-19 -Final Report Bridging the Gap at Warp Speed -Delivering Options for Preventing and Treating Covid-19 Why do COVID death rates seem to be falling? Dexamethasone in Hospitalized Patients with Covid-19 -Preliminary Report Prevalence of Asymptomatic SARS-CoV-2 Infection SARS-CoV-2 Transmission among Marine Recruits during Quarantine Virology, transmission, and pathogenesis of SARS-CoV-2 Virological assessment of hospitalized patients with COVID-2019 False-positive COVID-19 results: hidden problems and costs Comparison of seven commercial RT-PCR diagnostic kits for COVID-19 Rethinking Covid-19 Test Sensitivity -A Strategy for Containment False Negative Tests for SARS-CoV-2 Infection -Challenges and Implications Understanding viral shedding of severe acute respiratory coronavirus virus 2 (SARS-CoV-2): Review of current literature Recurrence of positive SARS-CoV-2 viral RNA in recovered COVID Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia SnapShot: COVID-19 What Factors Increase the Risk of Complications in SARS-CoV-2-Infected Patients? A Cohort Study in a Nationwide Israeli Health Organization SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and metaanalysis Viral dynamics in mild and severe cases of COVID-19 Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China We thank the following for their contributions to our efforts: (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 12, 2021. All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.